Literature DB >> 33068862

Comprehensive analysis of the expression and prognostic value of CXC chemokines in colorectal cancer.

Li Yu1, Xinmei Yang2, Chuchu Xu1, Jiachun Sun3, Zhipeng Fang1, Hongming Pan4, Weidong Han5.   

Abstract

The C-X-C motif (CXC) chemokines play an important role in inflammatory processes and angiogenesis and are also associated with tumor development, progression and metastasis. They can be either promoting or inhibiting factors in colorectal cancers (CRC). The expression patterns and prognostic values of the CXC family still need further investigation. In this study, we investigated data related to transcription, translation, survival and tumor immune infiltration for CXC chemokines in patients with CRC from the ONCOMINE, GEPIA, cBioPortal, HPA and TIMER databases. We found that the expression levels of CXCL1-3, CXCL5, and CXCL8 were higher in CRC tissues than in colorectal tissues. Expression among stages significantly varied for CXCL1-3 and CXCL9-11. The survival analysis revealed that high transcriptional levels of CXCL4 and CXCL9-11 could serve as positive prognostic factors for patients with CRC. CXCL9-11 were highly associated with CD8+ T cells and natural killer (NK) cells in the tumor immune infiltration analysis, indicating their role in the antitumor immune response. This study implies that CXCL1-3, CXCL5, and CXCL8 are important factors during CRC oncogenesis and that CXCL9-11 could be new biomarkers for the prognosis of CRC.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemokines; Colorectal adenocarcinoma; Prognosis; Tumor-infiltrating immune cells

Mesh:

Substances:

Year:  2020        PMID: 33068862     DOI: 10.1016/j.intimp.2020.107077

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  8 in total

1.  Development of a novel chemokine signaling-based multigene signature to predict prognosis and therapeutic response in colorectal cancer.

Authors:  Xin Qi; Donghui Yan; Jiachen Zuo; Rui Wang; Jiajia Chen
Journal:  J Zhejiang Univ Sci B       Date:  2021-12-15       Impact factor: 3.066

2.  CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy.

Authors:  Yonggui Tian; Chunli Wen; Zhen Zhang; Yanfen Liu; Feng Li; Qitai Zhao; Chang Yao; Kaiyuan Ni; Shengli Yang; Yi Zhang
Journal:  Cancer Immunol Immunother       Date:  2022-03-29       Impact factor: 6.630

3.  Identification of a Genomic Instability-Related Long Noncoding RNA Prognostic Model in Colorectal Cancer Based on Bioinformatic Analysis.

Authors:  Yu Liang; Hong-Xu Sun; Bin Ma; Qing-Kai Meng
Journal:  Dis Markers       Date:  2022-06-07       Impact factor: 3.464

4.  BTG2 Serves as a Potential Prognostic Marker and Correlates with Immune Infiltration in Lung Adenocarcinoma.

Authors:  Xiao Zhen Zhang; Mao Jian Chen; Ping Ming Fan; Wei Jiang; Shi Xiong Liang
Journal:  Int J Gen Med       Date:  2022-03-08

5.  Establishment and validation of a novel invasion-related gene signature for predicting the prognosis of ovarian cancer.

Authors:  Leilei Liang; Jian Li; Jing Yu; Jing Liu; Lin Xiu; Jia Zeng; Tiantian Wang; Ning Li; Lingying Wu
Journal:  Cancer Cell Int       Date:  2022-03-15       Impact factor: 5.722

6.  Comprehensive analysis of prognostic value and immune infiltration of CXC chemokines in pancreatic cancer.

Authors:  Yanhua Jing; Fengjiao Wang; Ke Zhang; Zhen Chen
Journal:  BMC Med Genomics       Date:  2022-04-25       Impact factor: 3.622

Review 7.  Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer.

Authors:  Qian Zou; Xue Lei; Aijing Xu; Ziqi Li; Qinglian He; Xiujuan Huang; Guangxian Xu; Faqing Tian; Yuanlin Ding; Wei Zhu
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

Review 8.  CXCL1: Gene, Promoter, Regulation of Expression, mRNA Stability, Regulation of Activity in the Intercellular Space.

Authors:  Jan Korbecki; Katarzyna Barczak; Izabela Gutowska; Dariusz Chlubek; Irena Baranowska-Bosiacka
Journal:  Int J Mol Sci       Date:  2022-01-12       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.